Terapia z wykorzystaniem dojrzałych komórek macierzystych w leczeniu nietrzymania moczu u kobiet by Stangel-Wójcikiewicz, Klaudia et al.
Nr 5/2010378
    
Ginekol Pol. 2010, 81, 378-381
P R A C E  P O G L Ñ D O W E
  g in eko l og ia
 
Adult stem cells therapy for urine 
incontinence in women  
Terapia z wykorzystaniem dojrzaΠych komórek macierzystych w leczeniu 
nietrzymania moczu u kobiet
Stangel-Wójcikiewicz	Klaudia1,	Majka	Marcin2,	Basta	Antoni1,	Stec	Małgorzata2,	
Pabian	Wojciech1,	Piwowar	Monika3,	Chancellor	Michael	B4
1 Department of Gynecology and Oncology, Collegium Medium Jagiellonian University of Kraków,
2 Department of Transplantology, Collegium Medicum Jagiellonian University of Kraków, 
3 Department of Bioinformatics and Telemedicine, Collegium Medicum Jagiellonian University of Kraków,
4 Department of Urology, William Beaumont Hospital, Royal Oak, MI, USA
 Abstract
The past few years brought high development in obtaining and culturing autologous adult stem cells. In this paper we 
review publications of experimental investigations and clinical trials of the muscle-derived cells and the application 
in the treatment of stress urinary incontinence among women.
Mesenchymal stem cells (MSCs) can be obtained from bone marrow but it is associated with a painful biopsy 
procedure. Collection of muscle-derived stem cells (MDSCs) is less harmful because the skeletal muscle biopsy is 
performed with a small caliber needle in local anesthesia.
The stem-based therapy could be the next step in the treatment of urinary incontinence.There are still many elements 
of therapy such as effectiveness or long-term side effects which need to be researched.
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 Streszczenie
Ostatnie lata przyniosły znaczący rozwój w pozyskiwaniu i hodowli autologicznych komórek macierzystych. 
W poniższej publikacji zawarliśmy przegląd doniesień naukowych oraz badań klinicznych dotyczących macierzy-
stych komórek mięśniowych i ich wykorzystania w leczeniu nietrzymania moczu u kobiet.
Dotychczasowa konieczność wykorzystania bolesnej procedury biopsji szpiku kostnego w celu otrzymania komó-
rek macierzystych typu mesenchymalnego, niosła z sobą ograniczenia. Możliwość pozyskania dojrzałych komórek 
macierzystych mięśniowych na drodze cienko igłowej biopsji mięśnia- w znacznym stopniu ułatwia jej powszechne 
zastosowanie. 
Terapia nietrzymania moczu w oparciu o komórki macierzyste jawi się jako kolejny krok w ewolucji leczenia 
nietrzymania moczu. Do wyjaśnienia pozostają jej długoterminowa skuteczność oraz ewentualne skutki uboczne.
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Introduction
Urinary	incontinence	is	a	disorder	observed	in	200	million	
people	worldwide.	It	affects	mainly	women,	as	a	result	of	minor	
pelvic	anatomy	and	sociologic	factors	[1].	Frequency	of	urinary	
incontinence	increases	with	age	and	is	also	associated	with	the	
decrease	 of	 sexual	 hormones	 [2].	 Escalation	 of	 symptoms	 is	
associated	with	the	number	of	factors	including	natural	delivery,	
heavy	birth	weight,	 vaginal	procedures,	 high	body	mass	 index	
(BMI),	and	chronic	diseases	[3].
In	developed	countries,	special	attention	should	be	paid	to	
the	costs	of	symptomatic	therapies,	i.e.,	uses	of	absorbent	pads	
or	 pant	 liners,	 and	 surgery.	 It	 is	 estimated	 that	 patients	 with	
urinary	incontinence	in	the	United	States	(USA),	75%	of	whom	
are	women,	 require	 annual	 expenditures	 of	 $16	 billion	 dollars	
(£9.987	 billion)	 toward	 symptomatic	 therapies.	 In	 the	 United	
Kingdom,	about	£424	million	($679	million)	is	spent	toward	this	
aim	annually.	Taking	 into	 consideration	 an	 aging	 trend	 and	 an	
increase	of	mean	life	expectancy	in	the	developing	countries,	the	
problem	of	urinary	incontinence	is	increasing	[4].
Due	 to	 a	 range	 of	 causes	 leading	 to	 urinary	 incontinence,	
the	 following	 types	 have	 been	 established:	 stress	 urinary	
incontinence	 (SUI),	 urge	 urinary	 incontinence	 (UUI),	 mixed	
urinary	 incontinence	 (MUI),	 and	 overflow	 incontinence.	 Each	
type	requires	specific	therapeutic	management	[5].	Gynecological	
examination	with	cough	 test,	pat	 test,	 and	urodynamic	 test	 are	
all	 the	 diagnostic	 standards.	 A	 combination	 of	 all	 these	 tests	
enables	a	definitive	diagnosis	and	a	plan	for	proper	therapeutic	
management	for	each	patient	[6].
The	most	 common	 form	 of	 urinary	 incontinence,	 causing	
the	highest	number	of	diagnostic	and	therapeutic	doubts,	is	stress	
urinary	incontinence.	According	to	the	International	Continence	
Society’s	(ICS’s)	definition,	stress	urinary	incontinence	is	caused	
by	excessive	urethral	mobility	or	 intrinsic	 sphincter	deficiency	
(ISD)	[7].
Stress urinary incontinence therapy 
in women – standard management
Surgical	 therapy	 is	 standard	 management	 in	 SUI.	 Classic	
surgical	 techniques,	 i.e.,	 Burch’s	 method	 (performed	 with	
laparoscopic	 access)	 or	 with	 use	 of	 various	 structural	 profile	
tapes	as	well	as	a	range	of	access	methods	(Tension	free	Vaginal	
Tape,	Trans	Obturator	Tape	procedures)	are	used	depending	on	
their	 indications	 [8].	 Minimally	 invasive	 procedures,	 such	 as	
tissue	fixation	system	(TFS)	and	TVT	Secure	(Gynacare®),	are	
also	novel	methods	[9].
Attempts	using	Teflon®,	collagen,	or	silicone	in	paraurethral	
injections	are	also	made.	All	 the	above	methods	are	associated	
with	some	complications	[10].	In	case	of	classic	colposuspension,	
bleeding	from	vascular	plexuses	may	bring	some	difficulties,	as	
it	requires	
advanced	operational	abilities	of	the	medical	personnel	[11].	
Erosion,	observed	in	3%	to	10%	of	patients,	inflammation,	and,	
in	 consequence,	 formation	 of	 so-called	 “rigid	 urethra”	 are	 the	
most	 serious	complications	of	 tapes.	Use	of	artificial	materials	
for	 injections	 is	 associated	 with	 local	 allergic	 reactions	 and	
difficulties	in	urine	flow.	As	optimal	management	does	not	exist,	
alternative	methods	are	continuously	sought.	
Hormonal	balance	in	a	treated	patient	is	of	crucial	importance	
before	surgery.	Many	studies	confirm	an	increased	frequency	of	
urinary	incontinence	in	women	of	perimenopausal	age.	Estrogen	
deficiency	causes	decreased	blood	flow	through	the	submucosal	
vascular	plexus	which	increases	local	atrophy.	For	these	reasons,	
use	of	local	estrogenic	preparations	in	the	preoperational	period	
is	recommended	[12].
Use of Stem Cells in Stress Urinary 
Incontinence Therapy
Recent	 years	 have	 brought	 significant	 development	 of	
genetic	 engineering	 techniques	 and,	 as	 a	 result,	 the	 ability	 to	
apply	therapeutic	use	of	myoblastic	and	fibroblastic	autologous	
stem	cells.		The	ability	to	repair	lower	urinary	tract	defects	with	
correctly	functioning	host	tissue,	without	risk	of	denervation	or	
revascularization,	 appears	 to	 be	 the	 ideal	 solution	 [13].	 In	 the	
future,	 it	will	enable	an	expansion	of	qualifications	for	women	
with	 SUI,	 who,	 for	 various	 reasons,	 cannot	 undergo	 surgical	
treatment.
Tissue	 stem	 cells	 are	 obtained	 from	 the	 striated	 muscles,	
adipose	tissue,	and	bone	marrow.	These	cells	have	the	ability	to	
differentiate	into	properly	functioning	smooth	and	striated	muscle	
tissue	[14].	With	administration	into	the	paraurethral	region,	they	
contribute	to	the	increase	of	urethral	occlusion	pressure	and	the	
restoration	of	normal	urinary	continence.
Use of Various Cell Populations 
Bone	marrow	is	a	source	of	hematopoietic	stem	cells	and	Bone	
marrow	is	a	source	of	hematopoietic	stem	cells	and	mesenchymal	
stem	cells	(MSCs).	MSC	have	an	ability	to	differentiate,	both	in	
vitro	and	in	vivo,	into	adipocytes,	osteocytes,	chondrocytes,	and	
muscular	cells,	as	well	as	non-mesenchymal	cells	(endodermic	or	
nervous	cells)	[15].	Unfortunately,	 their	collection	technique	is	
associated	with	the	painful	bone	marrow	biopsy	and,	as	a	result,	
will	have	some	limitations	[16].	
The	above-referenced	encourages	scientists	to	use	so-called	
“mature”	stem	cells	 that	can	be	collected	 from	striated	muscle	
(muscles	of	arm	or	thigh)	with	biopsy	under	local	anesthesia	in	
therapeutic	SUI	models	and	enables	the	gain	of	muscle-derived	
stem	cells	 (MDSCs)	 and	 adipose-derived	 stem	cells	 (ADSCs).	
Based	 on	 the	 promising	 results	 seen	 in	 MDSC	 therapy	 for	
other	conditions,	such	as	myocardial	infarction	as	described	by	
Oshima,	among	others,	studies	focusing	on	treatment	of	urinary	
incontinence	are	now	being	done	[17].	Some	of	the	obstacles	to	
overcome	include	survival	of	cells	following	a	transplant,	their	
ability	to	integrate	with	the	urethral	sphincter	muscle,	and	their	
innervation.
Qu	 and	 associates	 from	 Pittsburgh,	 Pennyslvania,	 USA,	
has	 evaluated	 ways	 to	 improve	 the	 survival	 of	 transplanted	
myoblasts	in	the	treatment	of	Duchenne	muscular	dystrophy.	It	
has	been	observed	that	myoblasts	expressing	an	inhibitor	of	the	
inflammatory	cytokine,	IL-1,	are	associated	with	a	higher	rate	of	
survival	[18].
According	 to	 Yokoyama	 et	 al.,	 MDSCs	 present	 some	
advantages	 in	 SUI	 treatment.	 Collecting	 them	 from	 and	 using	
them	in	the	same	patient	practically	eliminates	the	risk	of	allergic	
or	immunologic	reaction	that	could	occur	if	using	injections	with	
collagen	[19].	
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The	 next	 important	 element	 is	 the	 ability	 of	 the	 above-
mentioned	cells	to	form	junctions	with	postmitotic	multinucleated	
myotubes,	which	differ	from	the	fibroblasts	that	do	not	present	
the	 tendency	 for	 migration	 and,	 consequently,	 urine	 retention	
[20].	Their	most	important	trait,	however,	is	their	ability	to	form	
myotubes	and	myofibers	with	reinnervation	that	enables	them	to	
build	into	the	structure	of	the	damaged	muscle	as	a	physiologically	
functional	 unit	 [21].	This	 finding	was	 confirmed	 in	 studies	 on	
rat	models	by	the	Chermansky	et	al.,	which	observed	junctions	
between	MDSCs	in	striated	muscles	layer	4	weeks	after	injection.	
Evaluation	of	leak	point	pressure	(LPP)	value	in	the	group	with	
MDSCs	was	significantly	higher	 than	 the	control	group	of	rats	
with	denervation	[22].
MDCs	(muscle-derived	cells)	and	fibroblasts	were	used	 in	
research	by	Yokoyama	on	rat	model.	Although	both	MDCs	and	
fibroblasts	 injection	 increased	 the	 LPP	 in	 a	 SUI,	 only	MDCs	
significantly	 improved	 urethral	 muscle	 strip	 contractility	 [23].	
Chancellor	 and	 associates	 evaluated	 lidocaine’s	 influence	 on	
MDCs	in	the	in	vitro	and	in	vivo	conditions	[24].	Earlier	studies	
suggested	 neurotoxicity	 of	 this	 substance.	 Negative	 influences	
on	 corneal	 epithelial	 cells,	 urothelial	 cells,	 pneumocytes,	 and	
chondrocytes	were	also	described.	The	study’s	results,	therefore,	
eliminated	the	use	of	lidocaine	as	local	anaesthesia.	Studies	on	
the	rat	model	did	not	confirm	the	above	theses	and	LPP	values	
after	therapy	with	MDCs	were	not	affected	by	use	of	analgesic	
substance.
Adipose-derived	stem	cells	are	also	used	in	SUI	therapy.	In	
2006,	Zeng	showed	an	 increase	 in	LPP	pressure	and	 improved	
urethra	 function	 on	 the	 rat	 model	 after	 use	 of	 ADSCs	 [25].	
Becker	and	Jakse	point	out	that,	despite	significant	developments	
in	 tissue	 engineering,	 there	 is	 still	 lack	 of	 scientific	 evidence	
relating	to	the	possibility	of	differentiating	autologous	stem	cells	
into	 urethral	mucosa	 (urothelium),	 neither	 in	 vivo	 nor	 in	 vitro	
[26].
The	unexplained	risk	of	carcinogenesis	associated	with	the	
ability	for	self-multiplication	remains	a	crucial	element	of	stem	
cell	therapy.	Mature	stem	cells	are	endowed	with	unpredictable	
plasticity	and,	as	progenitors,	may	differentiate	into	mature	cells	of	
different	tissue	types	[27,	28,	29].	Bone	marrow-derived	stromal	
cells	 (BM-SCs)	 characterize	 with	 particularly	 high	 plasticity.	
Their	 ability	 to	differentiate	 into	 the	non-haematopoietic	 cells/
lineages	was	shown	in	the	in	vivo	and	in	vitro	studies	[30,	31,	
32].
Clinical Trials
Results	 of	 studies	 on	 the	 animal	 model	 encouraged	
experimentation	with	human.	
The	first	reports	of	these	studies	were	published	in	2004	and	
2007.	The	application	of	MDSCs	in	the	therapy	of	stress	urinary	
incontinence	was	presented	in	the	original	study	that	appeared	in	
The	Lancet	in	June	2007.	The	purpose	of	the	publication	was	to	
compare	the	method	in	question	with	other	treatment	strategies.	
However,	due	to	certain	doubts	as	to	the	actual	existence	of	such	a	
trial,	the	editors	of	the	journal	decided	to	retract	the	article[33].	
A	 study	on	 the	use	of	 “pure”	MDSC	cells	 in	SUI	 therapy	
involving	eight	women	was	published	in	2008.	Carr	et	al.	used	
biopsy	needles	for	collection	of	samples	[34].	MDSCs	isolated	
in	 the	 laboratory	 were	 administered	 to	 patients	 under	 local	
anaesthesia	via	one	of	 three	methods	as	 follows:	 three	women	
obtained	 transurethral	 injection	with	 8	mm	 needles	 in	 the	 3rd	
and	 9th	 hours,	 two	 patients	 were	 injected	 transurethrally	with	
10	mm	needles	in	4	places	(the	3rd,	6th,	9th,	and	12th	hours);	and	
the	 remaining	 three	were	 injected	 in	4	places	but	25G	needles	
were	 used.	The	 patients	 in	 the	 third	 group	 received	 additional	
injections	three	months	after	 the	first	procedure,	again	 in	 the	4	
locations	described	above.
Mean	observation	time	was	17	months.	Among	five	women	
available	for	follow-up	study,	one	patient	presented	with	totally	
controlled	 urination.	 Two	 more	 patients	 reported	 significant	
improvement	 and	 received	 further	 injections	 4	 and	 8	 months	
after	their	first	procedures.	No	adverse	reactions	to	the	treatment	
were	described.
Results	 of	 the	 above	 studies	 are	 very	 encouraging.	
Multicenter	studies,	the	use	of	various	cell	types,	and	verification	
of	 their	 administration	 procedures	 enable	medical	 scientists	 to	
form	 objective	 conclusions	 on	 the	 efficacy	 of	 using	 stem	 cell	
therapy	for	stress	urinary	incontinence	in	the	future.
Stem	cell-based	therapy	is	not	merely	a	“wish	of	the	future.”	
This	 type	 of	 therapy	 is	 currently	 being	 used	 as	 a	 promising	
alternative	 treatment	 for	 many	 diseases,	 including	 myocardial	
infarction	and	Duchenne	muscular	dystrophy.	Due	to	legal	and	
ethical	challenges,	the	use	of	embryonic	stem	cells	is	not	widely	
accepted.	Therefore,	the	discovery	of	mature	tissue	stem	cells	has	
helped	researchers	avoid	many	reservations	[35].	
However,	 several	 unexplained	 elements	 of	 therapy	 exist,	
including	its	effectiveness,	long-term	side	effects,	and	the	stem	
cells’	ability	for	carcinogenesis.
Yoo	 and	 associates	 from	 Wake	 Forest,	 North	 Carolina	
USA,	 presented	 a	 report	 on	 current	 tendencies	 in	 the	 use	 of	
cell	 therapy	 and	 previous	 achievements	 in	 explant	 culture,	
also	 in	urogynecology,	 at	 the	38th	Meeting	of	 the	 International	
Continence	 Society	 (ICS)	 in	Cairo,	 Egypt,	 in	 2008.	There,	 he	
declared	completed	transplantation	of	the	urethra,	vagina,	ureter,	
and	the	bladder.	Yoo’s	research	team	is	currently	working	on	the	
development	of	kidney,	blood	vessel,	and	heart	valve	tissues	with	
the	use	of	biological	scaffles.
There	are	several	on-going	clinical	trials	and	investigations,	
including	the	work	of	our	gynecology	department	that	will	help	
further	define	the	future	role	of	cell-based	therapies	for	urinary	
incontinence.
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